DevQuartzabout 6 hours ago
AbbVie buys drug developer for nearly $11 billion
1 min read
AbbVie is acquiring an eczema and asthma drug developer for nearly $11 billion. The deal adds a late-stage pipeline asset to AbbVie's immunology portfolio. The acquisition targets a developer with treatments for inflammatory conditions.
Level
Hype check
Tap to vote and see what everyone thinks.
